Gilead Agrees $5 Billion Tubulis Acquisition To Expand Cancer Drug Pipeline [Yahoo! Finance]
Pfizer, Inc. (PFE)
Last pfizer, inc. earnings: 4/28 06:45 am
Check Earnings Report
US:NYSE Investor Relations:
investors.pfizer.com/investors-overview/default.aspx
Company Research
Source: Yahoo! Finance
cancer therapies, agreeing to acquire Germany-based Tubulis GmbH for up to $5 billion. The deal includes $3.15 billion in upfront cash and as much as $1.85 billion tied to milestones, with closing expected in the second quarter. Gilead ( NASDAQ:GILD ) shares slipped less than 1% in premarket trading, suggesting investors are balancing near-term dilution against what could be longer-term pipeline expansion. Warning! GuruFocus has detected 2 Warning Sign with GILD. Is GILD fairly valued? Test your thesis with our free DCF calculator. The strategic focus here centers on antibody-drug conjugates, or ADCs, a fast-growing class of therapies designed to deliver potent cancer-killing agents directly into tumors. The space has been attracting significant capital and consolidation, including Pfizer Inc.'s $43 billion acquisition of Seagen Inc. in 2023. Tubulis brings both platform capabilities and clinical-stage programs targeting ovarian and lung cancers, alongside existing collaboration
Show less
Read more
Impact Snapshot
Event Time:
PFE
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PFE alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PFE alerts
High impacting Pfizer, Inc. news events
Weekly update
A roundup of the hottest topics
PFE
News
- Pfizer (PFE) is now covered by CICC Research. They set an "outperform" rating on the stock.MarketBeat
- UBS Adjusts Pharma Outlook, Increases Pfizer (PFE) Price Target [Yahoo! Finance]Yahoo! Finance
- Pfizer (PFE) had its price target raised by UBS Group AG from $25.00 to $27.00. They now have a "neutral" rating on the stock.MarketBeat
- Pfizer (PFE) had its price target raised by Morgan Stanley from $27.00 to $28.00. They now have an "equal weight" rating on the stock.MarketBeat
- Pfizer (PFE) had its price target lowered by Bank of America Corporation from $27.00 to $26.00. They now have a "neutral" rating on the stock.MarketBeat
PFE
Earnings
- 2/3/26 - Beat
PFE
Sec Filings
- 4/16/26 - Form 4
- 4/10/26 - Form 3
- 4/1/26 - Form 4
- PFE's page on the SEC website